Geoff Meacham
Stock Analyst at Citigroup
(4.43)
# 362
Out of 5,182 analysts
297
Total ratings
60.85%
Success rate
14.66%
Average return
Main Sectors:
Stocks Rated by Geoff Meacham
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GILD Gilead Sciences | Maintains: Buy | $156 → $165 | $133.29 | +23.79% | 10 | Apr 13, 2026 | |
| BIIB Biogen | Maintains: Neutral | $215 → $190 | $185.95 | +2.18% | 20 | Apr 13, 2026 | |
| MGTX MeiraGTx Holdings | Maintains: Buy | $14 → $16 | $10.17 | +57.33% | 2 | Mar 27, 2026 | |
| APGE Apogee Therapeutics | Maintains: Buy | $95 → $125 | $90.86 | +37.57% | 3 | Mar 24, 2026 | |
| MRK Merck & Co. | Maintains: Neutral | $120 → $125 | $112.56 | +11.05% | 12 | Mar 20, 2026 | |
| PTGX Protagonist Therapeutics | Maintains: Buy | $115 → $125 | $105.89 | +18.05% | 5 | Mar 19, 2026 | |
| BNTX BioNTech SE | Maintains: Buy | $145 → $130 | $111.60 | +16.49% | 3 | Mar 11, 2026 | |
| BMRN BioMarin Pharmaceutical | Maintains: Buy | $97 → $85 | $54.62 | +55.62% | 4 | Mar 11, 2026 | |
| VRTX Vertex Pharmaceuticals | Maintains: Buy | $575 → $585 | $436.59 | +33.99% | 7 | Mar 10, 2026 | |
| SRRK Scholar Rock Holding | Maintains: Buy | $55 → $58 | $48.10 | +20.58% | 2 | Mar 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $110 → $120 | $88.07 | +36.26% | 8 | Mar 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $85 | $73.35 | +15.88% | 1 | Mar 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $110 → $115 | $114.98 | +0.02% | 2 | Feb 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $19 | $17.59 | +8.02% | 6 | Feb 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $60 → $64 | $59.39 | +7.76% | 9 | Feb 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $315 → $345 | $344.86 | +0.04% | 14 | Feb 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $235 → $230 | $205.12 | +12.13% | 22 | Jan 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $48 → $50 | $49.48 | +1.05% | 4 | Jan 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $15.17 | +229.60% | 1 | Jan 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $58 → $49 | $15.46 | +216.95% | 3 | Dec 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $26 | $27.31 | -4.80% | 7 | Dec 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $8 | $2.73 | +193.04% | 6 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $50 → $75 | $70.63 | +6.19% | 10 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $660 → $700 | $747.36 | -6.34% | 24 | Oct 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $30 → $28 | $54.23 | -48.37% | 11 | Oct 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $50 | $32.48 | +53.94% | 2 | Oct 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $45 → $50 | $42.45 | +17.79% | 4 | Oct 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $78 → $93 | $55.54 | +67.45% | 4 | Oct 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $12 → $14 | $10.83 | +29.27% | 3 | Aug 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $50 → $54 | $76.18 | -29.12% | 6 | Jun 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sell | $6 | $8.49 | -29.33% | 1 | Jun 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $7 → $1 | $2.32 | -56.90% | 3 | Apr 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $112 → $4 | $1.15 | +247.83% | 5 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,150 → $1,100 | $903.02 | +21.81% | 9 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $120 → $20 | $23.92 | -16.37% | 3 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $22 → $31 | $36.69 | -15.51% | 2 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $180 → $170 | $226.16 | -24.83% | 3 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $17 | $0.95 | +1,693.63% | 1 | Aug 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $24 | $1.13 | +2,023.89% | 4 | Nov 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $12 → $4 | $13.26 | -69.83% | 2 | Jun 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $22.41 | +24.94% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $34 | $2.30 | +1,378.26% | 1 | Jul 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $35 | $1.92 | +1,722.92% | 4 | Jan 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $42 | $1.46 | +2,776.71% | 1 | Oct 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $20 | $0.26 | +7,666.99% | 2 | Sep 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underperform | $9 | $7.26 | +23.97% | 1 | Jun 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $60 | $9.11 | +558.62% | 1 | Jun 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $15 → $23 | $28.27 | -18.64% | 3 | Aug 5, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $90 → $82 | $96.22 | -14.78% | 9 | May 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $100 → $95 | $573.46 | -83.43% | 6 | Mar 1, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $300 → $80 | $19.97 | +300.60% | 3 | Dec 20, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 → $135 | $130.22 | +3.67% | 2 | Aug 1, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $10.67 | - | 4 | May 21, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $16 → $20 | $4.07 | +391.40% | 4 | May 3, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | n/a | $10.19 | - | 2 | Apr 5, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $127 → $158 | $308.43 | -48.77% | 5 | Nov 8, 2017 |
Gilead Sciences
Apr 13, 2026
Maintains: Buy
Price Target: $156 → $165
Current: $133.29
Upside: +23.79%
Biogen
Apr 13, 2026
Maintains: Neutral
Price Target: $215 → $190
Current: $185.95
Upside: +2.18%
MeiraGTx Holdings
Mar 27, 2026
Maintains: Buy
Price Target: $14 → $16
Current: $10.17
Upside: +57.33%
Apogee Therapeutics
Mar 24, 2026
Maintains: Buy
Price Target: $95 → $125
Current: $90.86
Upside: +37.57%
Merck & Co.
Mar 20, 2026
Maintains: Neutral
Price Target: $120 → $125
Current: $112.56
Upside: +11.05%
Protagonist Therapeutics
Mar 19, 2026
Maintains: Buy
Price Target: $115 → $125
Current: $105.89
Upside: +18.05%
BioNTech SE
Mar 11, 2026
Maintains: Buy
Price Target: $145 → $130
Current: $111.60
Upside: +16.49%
BioMarin Pharmaceutical
Mar 11, 2026
Maintains: Buy
Price Target: $97 → $85
Current: $54.62
Upside: +55.62%
Vertex Pharmaceuticals
Mar 10, 2026
Maintains: Buy
Price Target: $575 → $585
Current: $436.59
Upside: +33.99%
Scholar Rock Holding
Mar 4, 2026
Maintains: Buy
Price Target: $55 → $58
Current: $48.10
Upside: +20.58%
Mar 2, 2026
Maintains: Buy
Price Target: $110 → $120
Current: $88.07
Upside: +36.26%
Mar 2, 2026
Initiates: Buy
Price Target: $85
Current: $73.35
Upside: +15.88%
Feb 24, 2026
Downgrades: Neutral
Price Target: $110 → $115
Current: $114.98
Upside: +0.02%
Feb 20, 2026
Maintains: Buy
Price Target: $15 → $19
Current: $17.59
Upside: +8.02%
Feb 6, 2026
Maintains: Neutral
Price Target: $60 → $64
Current: $59.39
Upside: +7.76%
Feb 4, 2026
Maintains: Neutral
Price Target: $315 → $345
Current: $344.86
Upside: +0.04%
Jan 27, 2026
Maintains: Neutral
Price Target: $235 → $230
Current: $205.12
Upside: +12.13%
Jan 27, 2026
Maintains: Buy
Price Target: $48 → $50
Current: $49.48
Upside: +1.05%
Jan 9, 2026
Initiates: Buy
Price Target: $50
Current: $15.17
Upside: +229.60%
Dec 2, 2025
Maintains: Buy
Price Target: $58 → $49
Current: $15.46
Upside: +216.95%
Dec 2, 2025
Reinstates: Neutral
Price Target: $26
Current: $27.31
Upside: -4.80%
Nov 18, 2025
Maintains: Buy
Price Target: $9 → $8
Current: $2.73
Upside: +193.04%
Nov 5, 2025
Maintains: Neutral
Price Target: $50 → $75
Current: $70.63
Upside: +6.19%
Oct 29, 2025
Maintains: Buy
Price Target: $660 → $700
Current: $747.36
Upside: -6.34%
Oct 23, 2025
Maintains: Neutral
Price Target: $30 → $28
Current: $54.23
Upside: -48.37%
Oct 17, 2025
Maintains: Buy
Price Target: $42 → $50
Current: $32.48
Upside: +53.94%
Oct 17, 2025
Maintains: Buy
Price Target: $45 → $50
Current: $42.45
Upside: +17.79%
Oct 17, 2025
Maintains: Buy
Price Target: $78 → $93
Current: $55.54
Upside: +67.45%
Aug 27, 2025
Upgrades: Buy
Price Target: $12 → $14
Current: $10.83
Upside: +29.27%
Jun 25, 2025
Maintains: Buy
Price Target: $50 → $54
Current: $76.18
Upside: -29.12%
Jun 17, 2025
Initiates: Sell
Price Target: $6
Current: $8.49
Upside: -29.33%
Apr 2, 2025
Downgrades: Underperform
Price Target: $7 → $1
Current: $2.32
Upside: -56.90%
Jan 7, 2025
Downgrades: Underperform
Price Target: $112 → $4
Current: $1.15
Upside: +247.83%
Oct 31, 2024
Maintains: Buy
Price Target: $1,150 → $1,100
Current: $903.02
Upside: +21.81%
Oct 30, 2024
Downgrades: Underperform
Price Target: $120 → $20
Current: $23.92
Upside: -16.37%
Oct 18, 2024
Upgrades: Buy
Price Target: $22 → $31
Current: $36.69
Upside: -15.51%
Apr 17, 2024
Maintains: Neutral
Price Target: $180 → $170
Current: $226.16
Upside: -24.83%
Aug 21, 2023
Maintains: Buy
Price Target: $19 → $17
Current: $0.95
Upside: +1,693.63%
Nov 1, 2022
Downgrades: Underperform
Price Target: $24
Current: $1.13
Upside: +2,023.89%
Jun 8, 2022
Downgrades: Neutral
Price Target: $12 → $4
Current: $13.26
Upside: -69.83%
Aug 10, 2021
Initiates: Buy
Price Target: $28
Current: $22.41
Upside: +24.94%
Jul 13, 2021
Initiates: Buy
Price Target: $34
Current: $2.30
Upside: +1,378.26%
Jan 15, 2021
Downgrades: Neutral
Price Target: $35
Current: $1.92
Upside: +1,722.92%
Oct 20, 2020
Initiates: Buy
Price Target: $42
Current: $1.46
Upside: +2,776.71%
Sep 8, 2020
Reinstates: Buy
Price Target: $20
Current: $0.26
Upside: +7,666.99%
Jun 25, 2020
Reinstates: Underperform
Price Target: $9
Current: $7.26
Upside: +23.97%
Jun 25, 2020
Reinstates: Buy
Price Target: $60
Current: $9.11
Upside: +558.62%
Aug 5, 2019
Maintains: Equal-Weight
Price Target: $15 → $23
Current: $28.27
Upside: -18.64%
May 3, 2019
Downgrades: Equal-Weight
Price Target: $90 → $82
Current: $96.22
Upside: -14.78%
Mar 1, 2019
Maintains: Underweight
Price Target: $100 → $95
Current: $573.46
Upside: -83.43%
Dec 20, 2018
Downgrades: Equal-Weight
Price Target: $300 → $80
Current: $19.97
Upside: +300.60%
Aug 1, 2018
Maintains: Overweight
Price Target: $100 → $135
Current: $130.22
Upside: +3.67%
May 21, 2018
Downgrades: Underweight
Price Target: n/a
Current: $10.67
Upside: -
May 3, 2018
Maintains: Equal-Weight
Price Target: $16 → $20
Current: $4.07
Upside: +391.40%
Apr 5, 2018
Downgrades: Equal-Weight
Price Target: n/a
Current: $10.19
Upside: -
Nov 8, 2017
Maintains: Overweight
Price Target: $127 → $158
Current: $308.43
Upside: -48.77%